Experimental chemotherapy with N'N'-bis(2-chloroethyl)-N-nitrosourea (BCNU) in autochthonous neurogenic tumors of the rat transplacentally induced by ethylnitrosourea
- PMID: 7130253
- PMCID: PMC12253454
- DOI: 10.1007/BF00402057
Experimental chemotherapy with N'N'-bis(2-chloroethyl)-N-nitrosourea (BCNU) in autochthonous neurogenic tumors of the rat transplacentally induced by ethylnitrosourea
Abstract
Autochthonous neurogenic tumors of the rat induced by transplacental application of ethylnitrosourea were used for the first time to study their suitability as tumor models for experimental chemotherapy. Of 189 transplacentally treated rats, 87% developed neurogenic tumors. After the initial clinical diagnosis of a neurogenic tumor, additional malignant tumors often occurred. The mean number of neurogenic tumors from 62 untreated control rats increased from 1.0 per rat at the time of randomization to 1.2 as revealed by autopsy and 1.5 tumors by histological examinations. Out of all neurogenic tumors, tumors of the brain were observed in 31%, tumors of cranial nerves in 36% (90% tumors of trigeminal nerve), tumors of spinal cord in 21%, and tumors of peripheral nerves in 10%. The median survival time until natural death of 62 control rats was 228 days. Rats with tumors of peripheral nerves lived shortest, followed by rats with tumors of cranial nerves, tumors of the spinal cord, and brain tumors. Brain tumors were mainly astrocytomas and oligodendrogliomas. The survival time of untreated rats from randomization to natural death was longest for those with brain tumors, followed by tumors of peripheral nerves, cranial nerves, and tumors of the spinal cord. There was great variation in survival time from a few days to more than 6 months. To study the responsiveness to chemotherapy, 62 rats received BCNU as a single intravenous dose of 9 and later 10 mg/kg. Sixty-two untreated control rats had a median survival time of 36 days (95% confidence interval 26-52 days), the treated rats 43.5 days (26-62 days). The difference was not statistically significant. BCNU produced a remission or a no change of neurologic symptoms in 60% (37 out of 62) in comparison to 39% (24 out of 62) in the control group (p less than 0.05). The advantages and disadvantages of the present models are discussed. Due to methodical problems and the marginal response to BCNU, autochthonous neurogenic tumors of the rat are not suitable as models for chemotherapeutic studies.
Similar articles
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Management of faecal incontinence and constipation in adults with central neurological diseases.Cochrane Database Syst Rev. 2013 Dec 18;(12):CD002115. doi: 10.1002/14651858.CD002115.pub4. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2014 Jan 13;(1):CD002115. doi: 10.1002/14651858.CD002115.pub5. PMID: 24347087 Updated.
Cited by
-
Current brain tumour models with particular consideration of the transplantation techniques. Outline of literature and personal preliminary results.Acta Neurochir (Wien). 1986;79(1):35-41. doi: 10.1007/BF01403463. Acta Neurochir (Wien). 1986. PMID: 3953322
References
-
- Bürkle G (1975) Autochthone Tiertumoren als Testmodelle für die Chemotherapie mit Bleomycin. In: Wilmanns W (ed) Bleomycin. Experimentelle Grundlagen und erste klinische Ergebnisse. Ahnen KG, Laupheim
-
- Druckrey H, Schagen B, Ivankovic S (1970) Erzeugung neurogener Malignome durch einmalige Gabe von ÄNH an neugeborene und junge BD-IX-Ratten. Z Krebsforsch 74:141–161 - PubMed
-
- Fiebig HH, Schmähl D (1977a) Synergismus von Adriamycin mit 5-Fluorouracil, mit Prednisolon und mit Cyclophosphamid am autochthonen Mammakarzinom der Ratte. Klin Wochenschr 55:445–450 - PubMed
-
- Fiebig HH, Schmähl, D (1977b) The effect of ovariectomy, Tamoxifen and the combination Adriamycin and 5-FU on 7,12Dimethylbenz(a)-anthracene induced mammary cancer of the rat. Oncology 34:58–61 - PubMed
-
- Fiebig HH, Schmähl D (1978) Das experimentelle Mammakarzinom als Modell für chemotherapeutische Studien. In: Schmähl D (Hrsg) Behandlung und Nachbehandlung des Mammakarzinoms. Thieme, S 36–56)
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous